Fosamax Information
Fosamax, also known as alendronate, is a medication used to treat bone loss. Fosamax is manufactured and sold by Merck; the same company that manufactured Vioxx.
For several years, Fosamax has been implicated in the serious necrosis of the jaw and other bones, a condition known as "osteonecrosis" (ONJ), often referred to as "bone death."
Studies suggest a link between the use of Fosamax and osteonecrosis. This condition is associated with the interference of the blood supply to the bone and the consequential damage that occurs. Fosamax has been commonly used by cancer patients and post-menopausal women.
Many reported cases of complications occur following a dental procedure. In addition, in 2010, the U.S. FDA issued a warning regarding femur fractures, especially atypical fractures. On October 13, 2010, the FDA directed that labels for biphosphonates contain this warning.
Atypical subtrochanteric femur fractures are fractures in the bone just below the hip joint. Diaphyseal femur fractures occur in the long part of the thigh bone. These fractures are very uncommon, accounting for less than 1% of all hip and femur fractures. These unusual femur fractures have been reported primarily in women who use bisphosphonates, such as Fosamax.
Clark, Perdue & List has substantial experience with pharmaceutical injury claims. If you were prescribed Fosamax and have suffered bone necrosis, you may a have claim. Contact the Ohio Fosamax attorneys at Clark, Perdue & List or call us at 1-866-603-1668 today.
